Acknowledgments
The patients in this manuscript have given written informed consent to the publication of their case details.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Journal of Dermatological Treatment
Volume 33, 2022 - Issue 3
Letters to the Editor
Rituximab monotherapy in mild pemphigus
Ali Nilia Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran
https://orcid.org/0000-0002-1286-1858
https://orcid.org/0000-0002-1286-1858, Hamidreza Mahmoudia Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iranhttps://orcid.org/0000-0002-1890-1005
https://orcid.org/0000-0002-1890-1005, , Soheil Tavakolpoura Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iran;b Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USAhttps://orcid.org/0000-0002-6765-8830
https://orcid.org/0000-0002-6765-8830, Ali Salehi Farida Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, Iranhttps://orcid.org/0000-0003-3135-1076
https://orcid.org/0000-0003-3135-1076, & Maryam Daneshpazhooha Autoimmune Bullous Diseases Research Center, Tehran University of Medical Sciences, Tehran, IranCorrespondence[email protected]
https://orcid.org/0000-0003-1020-8895
https://orcid.org/0000-0003-1020-8895 show all![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})